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Background: Aberrant DNA methylation is an acquired epigenetic alteration that serves as an alternative to genetic
defects in the inactivation of tumor suppressor genes and other genes in diverse human cancers. Gastric carcinoma
is one of the tumors with a high frequency of aberrant methylation in promoter region. Hence we investigated the
promoter methylation status and expression level of HOXA11 gene which may involve in GC development.
Methods: Thirty-two surgical excised gastric cancer specimens, twelve paired adjacent non-cancerous specimens
and seven normal gastric mucosas were examined. The methylation status and expression level of HOXA11 gene
were determined by bisulfite sequencing polymerase chain reaction (BSP), real-time polymerase chain reaction
(RT-PCR) and immunohistochemistry (IHC) respectively. HOXA11 expression was knocked-down with siRNA to mimic
HOXA11 gene hypermethylation and ability of cell proliferation and migration was determinate. In addition, we
analyzed and correlated the findings with clinicopathological features.
Results: The methylation level of HOXA11 gene in gastric cancer tissues and adjacent non-cancerous tissues were
higher than those in normal gastric mucosa (P < 0.05). The methylation level was higher in TNM III and IV patients
of GC than those in TNM I and II patients (P < 0.05). The expression of HOXA11 mRNA and protein decreased in
normal gastric mucosa, peri-cancer tissue and GC (P < 0.05). HOXA11 expression was inversely correlated with DNA
methylation (P < 0.05). Knocked-down of HOXA11 expression with siRNA in BGC-823 cells enhanced cell proliferation
compared with control, but no significant different was observed in migration ability.
Conclusion: Hypermethylation and decreased expression of HOXA11 gene may be involved in the carcinogenesis and
development of GC and may provide useful information for the prediction of the malignant behaviors of GC. And the
expression of HOXA11 is impaired by DNA methylation. However, repression of HOXA11 expression promoted BGC-823
cell proliferation.
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Gastric cancer (GC) is one of the most common malignan-
cies of the digestive system and is a major cause of cancer
death in China. Because gastric cancer lacks early detective
and effective curing methods, especially to intermediate or
advanced stage ones, that have a poorer survival. Under-
standing the molecular mechanism that characterize cell
growth, cell cycle, apoptosis, angiogenesis and invasion has* Correspondence: kfszm@163.com; jishaoping@hotmail.com
1Department of Gastroenterology, Huaihe Hospital of Henan University,
Kaifeng, Henan Province 475000, China
2Department of Biochemistry and Molecular Biology, Medical School of
Henan University, Kaifeng, Henan Province 475004, China
Full list of author information is available at the end of the article
© 2014 Bai et al.; licensee BioMed Central Ltd.
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.enabled us to use new approaches to treat this disease in
clinical practice. Gastric carcinogenesis is thought to be a
multistep process that involves multiple genes, and epi-
genetic alterations in oncogenes, tumor suppressor genes,
DNA repair genes, cell cycle regulators and signaling mol-
ecules, which play an important role in the occurrence and
progression of GC. DNA methylation is one of the import-
ant research aspects in epigenetics [1,2]. Gene silencing as-
sociated with aberrant methylation of CpG islands is an
acquired epigenetic alteration that serves as an alternative
to genetic defects in the inactivation of tumor suppressor
and other genes in human cancers. A number of genesThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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cancer [3-6].
As specialized transcription factors, HOX genes play cru-
cial roles in modulating embryonic morphogenesis and cell
differentiation of the mammal, and are closely correlated
to tumorigenesis [7,8]. HOX genes in mammals are ar-
ranged into clusters (A, B, C, and D) on four different
chromosomes. The HOXA cluster, located within a 155-
kb-long genomic region on chromosome 7p15-7p14.2 con-
sists of 12 genes (11 HOX genes and EVX1). Highly dense
CpG islands are prevalent in most of the HOXA promoters
and the hypermethylation of these islands plays pivotal
roles in the control of HOXA gene expression. Among
HOXA genes, HOXA11 hypermethylation has recently
been reported in endometrial carcinoma, ovarian cancer,
glioblastoma multiforme and cervical cancer [9-12]. None-
theless, epigenetic changes and the effect of HOXA11 on
gastric cancer remain unclear. Thus, relationship between
HOXA11 hypermethylation and tumor development cur-
rently becomes an active exploring area in recent years.
In this study, we sought to identify potential targets of
methylation induced gene silencing, in which gene expres-
sion is down-regulated in response to aberrant methyla-
tion. We have analyzed the methylation status of HOXA11
promoter and evaluated its correlation with gene expres-
sion level, as well as with different clinicopathological
parameters. SiRNA was used to knock-down HOXA11 ex-
pression and mimic hypermethylation of HOXA11. Effects
of repression of HOXA11 expression on cell proliferation
and migration were determinate in BGC-823 cells, in
which repression of HOXA11 expression augments the
cell proliferation compared with control.
Results and discussion
Results
DNA methylation profile of HOXA11 gene in gastric cancer
tissues
The methylation frequencies of HOXA11 gene in gas-
tric cancer tissues, peri-cancer tissue and normal gastric
mucosa were 65.028±27.4645, 61.325±24.4066, 33.886±
25.6900. The methylation frequencies of HOXA11 in
cancer tissues, peri-cancer tissue specimens were higher
than those in normal gastric mucosa (P = 0.007, P =
0.035), but no difference was seen between the adjacent
non-cancerous specimens and normal gastric mucosa
(P < 0.05). Representative results of bisulfite sequence
analysis for gene promoters in gastric cancer samples
are shown in Figure 1.
Clinico-pathological correlations with methylation profile
The methylation level of HOXA11 gene was higher in
TNM III and IV patients of GC than that in TNM I and
IIpatients (P < 0.05, Table 1). Promoter methylation of
HOXA11 was found to be associated with lymph nodemetastasis (P < 0.05, Table 1). No significant association
was found between HOXA11 methylation status and
other clinicopathological features such as age, gender,
tumor size, differentiation degree and invasive depth in
GC (P> 0.05, Table 1).Expression level of HOXA11 mRNA in gastric cancer
The expression levels of HOXA11 mRNA were signifi-
cantly lower in human gastric cancer tissues than in
peri-cancer tissue and normal gastric mucosa (P < 0.05,
Figure 2). We found a marked decrease in HOXA11
levels correlating with higher stages of tumour. This
was statistically significant when comparing TNM I,II
to TNM III, IV (P < 0.05). There was a noticeable trend
with lower levels correlating with increasing age and
lymphatic metastasis. However, the mRNA expression
of HOXA11 gene had no relation to gender, tumor size,
differentiation degree and invasive depth in GC (P >
0.05, Table 2).Analysis of immunohistochemistry
HOXA11 protein expression was then determined by
IHC. Normal gastric mucosa tissue and the adjacent non-
tumoral gastric mucosa had remarkably higher HOXA11
expression than GC tissues which has a highest methyla-
tion level of HOXA11 (Figure 3C). A significant decreased
of HOXA11expression was observed in the adjacent non-
tumoral gastric mucosa with higher methylation level than
normal tissue (Figure 3B). In contrast, normal tissue has
a high expression of HOXA11, but low methylation of
HOXA11 promoter (Figure 3A).Repression of HOXA11 expression and cell proliferation and
migration
Two double-stranded RNA fragments were transfected
into GGC-823 cells with random RNA as control. The
result of RT-PCR shown that fragment-1 more effi-
ciently repressed HOXA11 expression compared with
fragment-2 or random RNA (Figure 4A). For cell prolif-
eration and migration assay, a reverse transfection was
carried out with fragment-1 to knock-down HOXA11
expression, mimicking repression of HOXA11 expres-
sion by promoter hypermethylation. The results shown
knocked-down of HOXA11 augmented the cell prolifer-
ation from third day compared with random RNA or in-
tact cells (Figure 4B); However, in wound healing assay,
we did not observe significant change of the cell migra-
tion rate when HOXA11 expression was repressed with
siRNA (Figure 4C), indicating the HOXA11 defect
seems to only promote cell proliferation but not aug-
ment invasion or metastasis.
Figure 1 Bisulfate-sequencing of HOXA11. Each row represents an individual cloned allele. Circles represent CpG sites and their spacing accurately
reflects the CpG density of the region. The black circles and blue arrows show methylated CpG sites; the white circles and red arrows show unmethylated
CpG sites. There are two representations of graph under the each row. (A) gastric cancer tissue, (B) peri-cancer tissue, (C) normal gastric mucosa.
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It is currently believed that genetic and epigenetic events
interact to help drive tumor progression [13]. The com-
bination of the two sides may provide a new viewpoint
to better understand the pathogenesis of gastric carcin-
oma [14]. Great attention has been aroused on the sig-
nificance of DNA methylation for early diagnosis and
prognosis prediction in malignant tumors [15]. Gastric
carcinoma (GC) is one of the most frequent malignan-
cies and remains the second leading cause of cancer-
related mortality in the world [16]. Although the clinical
outcome of gastric cancer has gradually improved, diag-
nosis of gastric carcinoma is still disappointing. Thus,
early detection of gastric cancer is a key measure to re-
duce the mortality and improve the prognosis of gastric
carcinoma [17]. Increasing evidence now suggests that,
in addition to genetic alterations, epigenetic changes, in-
cluding DNA methylation, histone modification and
RNA interference, also play important roles in the devel-
opment and progression of gastric carcinoma [18-20].
As a well-defined epigenetic mechanism, DNA methyla-
tion plays a major role in cancer through transcriptional
silencing of critical growth regulators such as tumorsuppressor genes, along with gene mutation and dele-
tions, ultimately leading to carcinogenesis [21].
In addition to genetic causes, tumors can also be con-
sidered an epigenetic disease [22]. DNA methylation is
the most important area of epigenetics which plays an
important role in genomic imprinting and in the silen-
cing of retrotransposon. In normal cells, DNA methyla-
tion may modulate compartmentalization of DNA to
assure that transcriptionally active chromatin regions
replicate earlier than the bulk transcriptionally inactive
chromatin. Regional hypermethylation observed during
tumor progression may involve in inactivating one of the
two X chromosomes. These changes in chromatin struc-
ture may, through direct transcriptional inactivation of
genes and allelic deletions, mediate the decreased ex-
pression of tumor suppressor genes associated with
tumor development [23]. Hypermethylation of tumor
suppressor genes has attracted much attention recently
and DNA methylation inhibitors are being tested as po-
tential anticancer agents [24,25]. Drugs that inhibit DNA
methylation may help patients live longer with fewer
side effects than conventional cytotoxic therapy. Aber-
rant methylation of HOXA11 gene promoter has been
Table 2 Clinico-pathological correlations with mRNA
expression
Variable mRNA expression of HOXA11 P value
















Within muscle layer 10(0.4830±0.0733)
Penetrating muscle layer 20(0.3470±0.1961)
Lymph node metastasis 0.018
Positive 20(0.3285±0.2068)
Negative 10(0.5200±0.1766)
Data were analyzed by t test.
Table 1 Clinico-pathological correlations with
methylation profile
Variable HOXA11 P value
















Within muscle layer 10(59.810±29.2551)
Penetrating muscle layer 12(67.400±26.9784)
Lymph node metastasis 0.049
Positive 22(71.414±23.8900)
Negative 10(50.980±30.7814)
Data were analyzed by t test.
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roles involved in GC have not been elucidated. Therefore,
further investigation into the roles of HOXA11 methyla-
tion in GC development and identification of its regulators
are necessary.Figure 2 Analysis of HOXA11 gene expression by quantitative
real-time reverse transcription-polymerase chain reaction.
(NC) normal gastric mucosa, (P) peri-cancer tissue, (T) gastric
cancer tissues.Homeobox (HOX) genes were originally discovered in
Drosophila melanogaster [29]. Several investigations
demonstrate that HOX genes act as transcriptional reg-
ulators involved in the process of cell to cell communi-
cation during normal morphogenesis, the alteration of
which may contribute to the development of cancer
[30,31]. HOX gene homology domain is able to bind to
specific DNA sequences, and to regulate gene transcription
[32]. However the mechanisms of HOX genes involved in
tumorigenesis have not been elucidated. HOXA11 is a
murine Abdominal-B-type homeobox gene that regulates
lower abdominal development in Drosophila, and control
differentiation of the müllerian ducts into the fallopian
tubes, uterus and cervix. Studies show that low expression
of HOXA11 gene has been found in various tumors, such
as ovarian cancer and endometrial cancer, and it plays the
role of tumor suppressor genes [33]. Previous research
has shown that high methylation and low expression of
HOXA11 gene is prevalent in gynecologic cancer. Because
HOXA11 gene is a developmental related gene, the major-
ity of researches have focused on its effects on the meso-
derm organ development and expression. The regulation
mechanism involved in tumors has not been elucidated.
Cary Miller et al. [34] observed that Wnt7a regulates the
A B C
Figure 3 Immunohistochemistry (IHC) of HOXA11 protein in gastric mucosa/cancer tissues which have different methylation levels of
HOXA11 gene promoter regions. (A) A typical staining of normal gastric mucosa tissues. (B) A typical staining of adjacent gastric mucosa
tissues. (C) A typical staining of gastric cancer tissues. Methylation levels of HOXA11 promoter: A<B<C.
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gene may associate with Wnt involved in regulatory net-
work of development. In this study, we find the methyla-
tion frequencies of HOXA11 in GC tissues and adjacent
cancer tissues are higher than those in normal gastric mu-
cosa (P < 0.05). Moreover, expression of HOXA11 gene is
down regulated when the promoter region is hypermethy-
lated, suggesting that HOXA11 gene may play an import-
ant repressor role in GC tumorigenesis, and aberrant
promoter methylation is the main reason causing loss or
down-regulation of HOXA11 gene, which may be involved
in the carcinogenesis of GC. Furthermore, we found that
hypermethylation of HOXA11 was significantly associated
with lymph node metastasis and TNM stage in gastric can-
cer (P < 0.05), but not significantly associated with other
clinicopathological factors such as sex, age, tumor size, dif-
ferentiation degree and invasive depth. Our results suggest
that hypermethylation of HOXA11 may therefore be an
important indicator of molecular biology for evaluating the
degree of malignancy and lymph node status of gastric
cancer. In addition, results in vitra shown HOXA11 may
control cell growth and its defect enhanced the cell prolif-
eration which may involved in carcinogenesis of GC. How-
ever, repression of HOXA11 did not significantly promote
the cell migration, indicating HOXA11 defect does not
augment cancer cell metastasis.
In conclusion, aberrant promoter methylation of
HOXA11 is a frequent event and may be one of the main
phenotypes that induces HOXA11 gene aberrant expres-
sion in GC. As a transcription regulator, loss and down-
regution of HOXA11 may lead silence of cancer suppressor
genes and excessive growth such as tumors. Hypermethyla-
tion of CpG islands may appear early in carcinogenesis
which facilitates malignant growths, suggesting that the de-
tection of DNA methylation from gastric juice and blood
samples could serve as a molecular marker for predictingtumor progression and prognosis. DNA methylation oc-
curred in tumors are easier to correct than to correct DNA
sequence mutations or genetic damage. How to restore
DNA expression by developing gene-targeting therapies by
reversing aberrant methylation is currently considered a
promising new approach of gastric cancer treatment. Since
aberrant methylation of HOXA11 genes is significantly cor-
related with pathobiological behaviors in GC, analysis of
DNA methylation could be used in tumor diagnosis, evalu-
ation of chemosensitivity and prognosis.Conclusions
Hypermethylation of HOXA11 gene promoter regions
may impair expression of HOXA11 gene. The aberrant
methylation may be involved in the carcinogenesis and
development of GC.Materials and methods
Patients and tissue specimens
From May 2012 to March 2013, 32 patients were histolog-
ically diagnosed with gastric adenocarcinoma, and were
prospectively recruited into this study from Huaihe Hos-
pital of Henan University (Henan, China). All patients had
given informed consent for specimen collection. Written
informed consent was obtained from the patient for the
publication of this report and any accompanying images.
This study was performed with the approval of the
Medical Ethical Committee of Huaihe Hospital of Henan
University. The mean age of the patients (20 males and 12
females) was 63.4 years (range, 36 to 85 years, Standard
Deviation 12.1), and none of the patients has received pre-
operative chemo- or radiotherapy. The cancerous tissue,
peri-cancer tissue (located 1.5 ~ 2 cm from the primary
tumor) and normal gastric mucosa (superficial gastritis pa-
tients) were bisected, one stored at –80°C immediately,
Figure 4 Ability of BGC-823 cell proliferation and migration was determined when HOXA11 expression was knocked-down with siRNA.
(A) Reverse-PCR revealed fragment-1 can efficiently knock down HOXA11 expression compared with fragment-2 or random control RNA. (B) Cell
growth curve was drawn following repression of HOXA11 expression. (C) Wound healing assay was determined after a reverse transfection of
RNAi and random RNA. The normal cells were used as control.
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bedded in paraffin for further use.
DNA isolation and bisulfite sequencing (BS) analysis
Genomic DNA was extracted and bisulfite-modified using
the EZ DNA Methylation-Direct Kit (Zymo Research,
America) according to the manufacturer’s instructions. In
brief, the tissue was chopped as fine as possible, and then
added into M-Digestion BufferR with 20 mg/ml of
proteinase-K. The samples were incubated at 50°C for 22
min and centrifuge at 10,000 g for 5 min. Add 20 μl of
sample to 130 μl of CT Conversion ReagentR solution in
a PCR tube, following incubating at 98°C for 8 minutes,
64°C for 3.5 hours. Add 600 μl of M-Binding BufferR into
a Zymo-Spin™ IC Column and load the sample into the
Zymo-Spin™ IC Column containing the M-Binding Buffer.
Mix by inverting the column several times. Centrifuge and
wash samples with M-wash buffer for 2 times. The sample
was eluted the in M-elution buffer.
The bisulfate modified DNA was used immediately or
stored at -20°C. The transcription initiation site: -2000bp of upstream sequence and 2200 bp of downstream se-
quence of the HOXA11 gene transcription initiation sites
were from NCBI. CpG Island Searcher online was used for
CpG islands analysis and the indicated CpG islands serve
as templates for design of primers in BS. The bisulfate
modified DNA was amplified by Touchdown-PCR using
Takara Taq Hot Start Version (Takara, Japan). Table 3 shows
the sequences of primers and annealing temperature used
in the polymerase chain reaction (PCR). The PCR products
were electrophoresed on 1.0% agarose gel and visualized
under UV illumination. After being purified with Quick Gel
Extraction Kit (CWBIO, China), PCR products were cloned
into the pGEM-T vector (Promega, America). By screening
of blue-white spot, ten clones of each specimen were se-
quenced using M13 forward or reverse primers.
Real-time reverse transcription-polymerase chain reaction
quantifies HOXA11 gene expression level
Total RNA was extracted with TRIzol reagent (Invitrogen,
USA) according to the manufacturer’s instructions and
samples were immediately processed or stored at -80°C
Table 3 Primers used for RT-PCR and BSP
Primers Sense sequences 5′-3′ Antisense sequences 5′-3′ Product size (bp) Annealing temperature(°C)
HOXA11 RT-PCR TATACCAAGTACCAGATCCGA TGAGATCTTAATCAAGAGAGT 374 50
HOXA11 BSP ATTTTTATATGTAAGAAATTG AAAGTTTCCATTCTAAACAAT 276 50
β-actin CACTGGCATCGTGATGGA GGCCATCTCTTGCTCGAA 210 56
Bai et al. Cancer Cell International 2014, 14:79 Page 7 of 8
http://www.cancerci.com/content/14/1/79until use. First-strand cDNA was generated using a first
strand cDNA synthesis kit (CWBIO, China). Primers used
for the PCR are listed in Table 3. A qRT-PCR assay based
on SYBR Green detection was carried out to examine the
level of the expression of HOXA11 gene. The endpoint
used in the real-time PCR quantification, Ct, is defined as
the PCR cycle number that crosses an arbitrarily placed
signal threshold. Gene expression was presented using a
modification of the 2-ΔΔCt 2 method, first described by
K. Livakin PE Biosystems Sequence Detector User Bulletin
2. The expression of each housekeeping gene was pre-
sented as 2-ΔCt, where ΔCt (ΔCtTime X-ΔCtTime 0) and
time 0 represent the 1 × expression of each gene.
Immunohistochemical staining (IHC)
The paraffin-embedded tissues blocks were sectioned at
4 μm thickness, deparaffinized in xylene, rehydrated in
graded ethanol solution and endogenous peroxidase activity
was blocked by incubation with 3% H2O2 in for 30 min
at room temperature. Then sections were immersed in
citrate-NaOH buffer (10 mM sodium citrate, pH 7.0) for 40
min at 92°C for restoration of antigenicity. The rehydrated
sections were incubated overnight at 4°C with rabbit anti-
human HOXA11 polyclonal antibody (1:500, ab28699,
Abcam, USA). The sections incubated with the first anti-
body were washed with Tris-buffered saline (TBS) and then
were incubated with MaxVision™ HRP-Polymer anti-Rabbit
IHC Kit (Maixin, Fuzhou, China) for 15 min at room
temperature. The sections were visualized using the DAB
Detection Kit (Maixin, Fuzhou, China) reaction followed by
counterstaining with hematoxylin. Negative control experi-
ments were done by omitting the primary antibody. The
immunohistochemical expression of HOXA11 was exam-
ined independently by two pathologists using light micro-
scopes without information of patients. The percentage of
positive tumor cells was graded semiquantitatively, and
each sample was assigned to one of the following categor-
ies: 0 (0–4%); 1 (5–29%); 2 (30–59%); or 3 (60–100%). The
intensity of immunostaining was determined as 0 (nega-
tive), 1 (weak), 2 (moderate), and 3 (strong). The immuno-
reactive score was calculated by multiplication of the grade
determined by the percentage of positive cells and the
staining intensity.
Cell culture and transfection
BGC-823 cells (derived from human gastric epithelial
adenocarcinoma) were cultured in DMEM (Dulbecco’sModified Eagle Medium) with 10% bovine calf serum in
5% of CO2 and 90% of relative humidity. To knock-down
HOXA11 expression, two RNA fragments were synthe-
sized for optimizing efficiency of expression inhibition as
following: Fragment-1(sense): 5′-GCCCAAUGACAUA
CUCCUA-3′ and fragment-2(sense): 5′-GCAGUCUCGU
CCAAUUUCU-3′. After transfection and comparison by
reverse-transcription PCR, fragment-1 has higher effi-
ciency in inhibiting HOXA11 expression and was used for
the following experiments. A reverse transfection was per-
formed according to the manufacturer’s recommendations
of Lipofectamine 2000 (Invitrogen) with random RNA as
negative control. The cells were seeded into 24-well plates
or 60-mm dishes following transfection for proliferation
curve and Wound healing assay.Cell proliferation and migration assay
BGC-823 cells were seeded to 24-well plates (5 × 103 cells/
well) with reverse transfection of siRNA and cultured at
37°C with 5% CO2. Three duplicate wells were set up for
RNAi, Random RNA and normal control. Cell number at
each well was counted for each triplicate every 24 h for 7
days. For wound healing assay, cells were plated into 60-
mm dishes before due day. The monolayer cells of 80%
confluent were scraped with sterile 20 μL pipette tips and
detached cells were washed away with warm PBS. The cells
migrated into the scraped areas were photographed every
day after scratch with an inverted microscopy equipped
with a digital camera. Ability of wound healing among three
groups was compared in parallel.Statistical analysis
Data were analyzed by the computer program SPSS 17.0,
using analysis of t test. Two sided P < 0.05 was consid-
ered to be significant.Competing interests
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